The International Myeloma Foundation (IMF) – the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward a cure – says that a flawed report assessing the value of myeloma drugs dangerously oversimplifies a complex issue and could result in limiting patient access to optimal treatments.
The report, drafted by the Institute for Clinical and Economic Review (ICER), will be the subject of a public hearing on Thursday, May 26. The report’s controversial conclusion that many of the new myeloma drugs are overpriced, with limited effectiveness, has drawn sharp criticism from concerned myeloma patients and doctors.